Cargando…
Antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma
BACKGROUND: Early recurrence after surgical resection is a hallmark of poor prognosis in hepatocellular carcinoma (HCC). To determine the proteomic background of early recurrence of HCC, we focused on apoptosis-related proteins. METHODS: Surgically resected tumor tissues were obtained from 80 patien...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078925/ https://www.ncbi.nlm.nih.gov/pubmed/27799868 http://dx.doi.org/10.1186/s12014-016-9130-0 |
_version_ | 1782462479481176064 |
---|---|
author | Morofuji, Noriaki Ojima, Hidenori Hiraoka, Nobuyoshi Okusaka, Takuji Esaki, Minoru Nara, Satoshi Shimada, Kazuaki Kishi, Yoshiro Kondo, Tadashi |
author_facet | Morofuji, Noriaki Ojima, Hidenori Hiraoka, Nobuyoshi Okusaka, Takuji Esaki, Minoru Nara, Satoshi Shimada, Kazuaki Kishi, Yoshiro Kondo, Tadashi |
author_sort | Morofuji, Noriaki |
collection | PubMed |
description | BACKGROUND: Early recurrence after surgical resection is a hallmark of poor prognosis in hepatocellular carcinoma (HCC). To determine the proteomic background of early recurrence of HCC, we focused on apoptosis-related proteins. METHODS: Surgically resected tumor tissues were obtained from 80 patients, including HCC tumor tissues, non-tumor tissues, and normal liver tissues. These samples were grouped in the discovery and validation sample sets. The expression level of 192 apoptosis-related proteins was monitored using 247 commercially available antibodies and western blotting. The intensity of protein bands was compared between the tumor and non-tumor tissues as well as between the patients who had recurrence within 2 years after surgery and those who did not. RESULTS: In the first screening, we used pooled samples. The intensity of 53 protein bands detected by 37 unique antibodies was higher in tumor tissues compared with normal liver tissues, especially tumor tissues from patients who had recurrence within 2 years after surgery. In the second screening, we examined individual samples used to make the pooled samples. Among the selected bands and antibodies, the intensity of 18 protein bands detected by 11 antibodies was higher in tumor tissues compared with that in normal tissues, especially tumor tissues from the patients with early recurrence after surgery. For the third screening, we examined the samples from newly enrolled patients using these 11 antibodies. Eighteen protein bands detected by six antibodies were selected by using the same criteria. The corresponding antigens included ERK1, PKG, Apaf1, BclX, phosphorylated c-abl, and PIASx1/2. CONCLUSIONS: We screened 192 apoptosis-related proteins using specific antibodies and western blotting. We identified 6 apoptosis-related proteins associated with carcinogenesis and early recurrence in HCC. The biological and clinical significance of the identified proteins are worth further investigation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12014-016-9130-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5078925 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-50789252016-10-31 Antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma Morofuji, Noriaki Ojima, Hidenori Hiraoka, Nobuyoshi Okusaka, Takuji Esaki, Minoru Nara, Satoshi Shimada, Kazuaki Kishi, Yoshiro Kondo, Tadashi Clin Proteomics Research BACKGROUND: Early recurrence after surgical resection is a hallmark of poor prognosis in hepatocellular carcinoma (HCC). To determine the proteomic background of early recurrence of HCC, we focused on apoptosis-related proteins. METHODS: Surgically resected tumor tissues were obtained from 80 patients, including HCC tumor tissues, non-tumor tissues, and normal liver tissues. These samples were grouped in the discovery and validation sample sets. The expression level of 192 apoptosis-related proteins was monitored using 247 commercially available antibodies and western blotting. The intensity of protein bands was compared between the tumor and non-tumor tissues as well as between the patients who had recurrence within 2 years after surgery and those who did not. RESULTS: In the first screening, we used pooled samples. The intensity of 53 protein bands detected by 37 unique antibodies was higher in tumor tissues compared with normal liver tissues, especially tumor tissues from patients who had recurrence within 2 years after surgery. In the second screening, we examined individual samples used to make the pooled samples. Among the selected bands and antibodies, the intensity of 18 protein bands detected by 11 antibodies was higher in tumor tissues compared with that in normal tissues, especially tumor tissues from the patients with early recurrence after surgery. For the third screening, we examined the samples from newly enrolled patients using these 11 antibodies. Eighteen protein bands detected by six antibodies were selected by using the same criteria. The corresponding antigens included ERK1, PKG, Apaf1, BclX, phosphorylated c-abl, and PIASx1/2. CONCLUSIONS: We screened 192 apoptosis-related proteins using specific antibodies and western blotting. We identified 6 apoptosis-related proteins associated with carcinogenesis and early recurrence in HCC. The biological and clinical significance of the identified proteins are worth further investigation. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12014-016-9130-0) contains supplementary material, which is available to authorized users. BioMed Central 2016-10-24 /pmc/articles/PMC5078925/ /pubmed/27799868 http://dx.doi.org/10.1186/s12014-016-9130-0 Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Morofuji, Noriaki Ojima, Hidenori Hiraoka, Nobuyoshi Okusaka, Takuji Esaki, Minoru Nara, Satoshi Shimada, Kazuaki Kishi, Yoshiro Kondo, Tadashi Antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma |
title | Antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma |
title_full | Antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma |
title_fullStr | Antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma |
title_full_unstemmed | Antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma |
title_short | Antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma |
title_sort | antibody-based proteomics to identify an apoptosis signature for early recurrence of hepatocellular carcinoma |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5078925/ https://www.ncbi.nlm.nih.gov/pubmed/27799868 http://dx.doi.org/10.1186/s12014-016-9130-0 |
work_keys_str_mv | AT morofujinoriaki antibodybasedproteomicstoidentifyanapoptosissignatureforearlyrecurrenceofhepatocellularcarcinoma AT ojimahidenori antibodybasedproteomicstoidentifyanapoptosissignatureforearlyrecurrenceofhepatocellularcarcinoma AT hiraokanobuyoshi antibodybasedproteomicstoidentifyanapoptosissignatureforearlyrecurrenceofhepatocellularcarcinoma AT okusakatakuji antibodybasedproteomicstoidentifyanapoptosissignatureforearlyrecurrenceofhepatocellularcarcinoma AT esakiminoru antibodybasedproteomicstoidentifyanapoptosissignatureforearlyrecurrenceofhepatocellularcarcinoma AT narasatoshi antibodybasedproteomicstoidentifyanapoptosissignatureforearlyrecurrenceofhepatocellularcarcinoma AT shimadakazuaki antibodybasedproteomicstoidentifyanapoptosissignatureforearlyrecurrenceofhepatocellularcarcinoma AT kishiyoshiro antibodybasedproteomicstoidentifyanapoptosissignatureforearlyrecurrenceofhepatocellularcarcinoma AT kondotadashi antibodybasedproteomicstoidentifyanapoptosissignatureforearlyrecurrenceofhepatocellularcarcinoma |